The global cell culture media market size is expected to reach USD 10.70 billion by 2030, registering a CAGR of 12.54% from 2024 to 2030, according to a new report by Grand View Research, Inc. Expansion of biosimilars and biologics, growth in stem cell research, and emerging bio manufacturing technologies for cell-based vaccines are the major factors which are likely to drive the market. For instance, in October 2021, the Australian Government funded the Australian-led stem cell research through USD 25 million in grants.
The expansion of clear, regulatory approval paths for biosimilars in emerging markets is generating great opportunities for biosimilar monoclonal antibodies. The availability of an approval pathway in the U.S., has led to new opportunities for bio manufacturers to enter major markets around the globe. Biosimilar versions of monoclonal antibodies have the probability to offer cost reductions of 25-30%, and many emerging market countries are vigorously developing pathways for approvals and are swiftly catching up. As this industry is expanding the key biopharmaceutical players are adopting robust culturing technologies to meet the increasing demand; thereby driving the growth of the market.
Moreover, there is growing interest in improving the stem cell culture, because this technology is being used extensively in research for studying the stem cell biology, as well as for therapeutic applications. Furthermore, funding related to this research field has augmented in recent years which has accelerated the growth of the market. In addition to this, key media manufacturers launched new products for stem cell research. For instance, in September 2021, Bio-Techne Corporation launched a novel medium for the maintenance and expansion of induced pluripotent stem cells having applications in both translational and research workflows.
The outbreak of COVID-19 pandemic has improved the demand for well-established cell-based vaccine production technologies. Moreover, it has given rise to a few scientific innovations, particularly in the production and testing of vaccine technology. For instance, the Vero line originated from the African green monkey kidney and has been extensively used for viral vaccine manufacturing. It has also been used for the development of various SARS-CoV variants. ProVeroTM1 Serum-free Medium is one such medium manufactured by Lonza Bioscience which is protein-free, and of non-animal origin designed to support the growth of Vero cells and MDCK.
Moreover, in many European countries, cell-based flu vaccines have been approved. A probable advantage of cell culture technology is that it authorizes faster start-up of the manufacturing of vaccines during the pandemic. Today, the development of superior biological models, the optimization of culture growth medium, and the reduced dependence on animal-derived components endure to drive the rapidly developing vaccine development.
On the other hand, ethical issues concerning the use of animal-derived products hinders the industry growth. For instance, FBS is collected from the blood of fetal calves is one of the major ethical issues of serum containing media. It is projected that 600,000 liters of FBS is achieved from up to 1.8 million bovine fetuses are produced globally every year, presenting momentous scientific and ethical challenges. To overcome this issue, numerous workshops were held in the past on the replacement of fetal bovine serum and possible ways to reduce the use of FBS in media.
Request a free sample copy or view report summary: Cell Culture Media Market Report
By product, the serum-free media (SFM) segment held the highest market share of 36.0% in 2023. The use of serum-free media signifies a significant tool, which allows the researchers to perform specific applications or grow a specific cell type without using serum.
The biopharmaceutical production segment dominated the market with a revenue share of 42.71% in 2023. Strategic activities by key biopharmaceutical companies, increasing R&D, demand for more reproducible and better-defined media and growing biosimilars market drives the segment growth
By type, the liquid media segment captured the highest revenue share of 62.9% in 2023. This is attributed to increasing number of biopharmaceutical manufacturers, both downstream and upstream, are switching from premixed powders to liquid media and hence, propelling market growth
By end-user, The pharmaceutical and biotechnology companies segment captured the highest revenue share of 34.25% in 2023, owing to the expansion of the current manufacturing capacities coupled with increasing prevalence of chronic disease which in turn demands for novel therapeutic drugs
North America dominated the regional market with a revenue share of 37.58% in 2023 due to the growth in the pharmaceutical and biotechnology industry, presence of high R&D investment, and the development of novel culture media products in the region
Asia Pacific is estimated to grow at the fastest CAGR of 14.92% during the forecast period owing to the increase in awareness associated with the use of the cell culture technique.
Grand View Research has segmented the global cell culture media market on the basis of on product, application, type, end-use, and region:
Cell Culture Media Product Outlook (Revenue, USD Million, 2018 - 2030)
Serum-free Media
CHO Media
BHK Medium
Vero Medium
HEK 293 Media
Other Serum-free media
Classical Media
Stem Cell Culture Media
Specialty Media
Chemically Defined Media
Other Cell Culture Media
Cell Culture Media Application Outlook (Revenue, USD Million, 2018 - 2030)
Biopharmaceutical Production
Monoclonal Antibodies
Vaccines Production
Other Therapeutic Proteins
Diagnostics
Drug Screening And Development
Tissue Engineering And Regenerative Medicine
Cell And Gene Therapy
Other Tissue Engineering And Regenerative Medicine Applications
Other Applications
Cell Culture Media Type Outlook (Revenue, USD Million, 2018 - 2030)
Liquid Media
Semi-solid And Solid Media
Cell Culture Media End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical And Biotechnology Companies
Hospitals And Diagnostic Laboratories
Research And Academic Institutes
Other End-users
Cell Culture Media Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Cell Culture Media Market
Sartorius AG
Danaher
Merck KGaA
Thermo Fisher Scientific, Inc.
FUJIFILM Corporation
Lonza
BD
STEMCELL Technologies
Cell Biologics, Inc.
PromoCell GmbH
"The quality of research they have done for us has been excellent..."